Physician profile
Michael Patrick Honan
NPI 1255424750
$1,147.59
in general payments reported to CMS, 2019-2025
24 companies · $20.19 in 2025
The $20.19 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $203 · 2022: $64.79 · 2023: $14.27 · 2024: $53.54 · 2025: $20.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $88.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $88.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $213.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $156.20 | 2019-2020 | |
| Novo Nordisk INC | $73.17 | 2019-2020 | |
| Allergan, INC. | $69.18 | 2019 | |
| Urovant Sciences INC | $46.80 | 2022 | |
| Vanda Pharmaceuticals INC. | $46.77 | 2019 | |
| Abbott Laboratories | $44.87 | 2019 | |
| Astellas Pharma US INC | $41.88 | 2019 | |
| Amgen INC. | $41.59 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $40.51 | 2019-2020 | |
| Glaxosmithkline, LLC. | $40.07 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $37.83 | 2019-2020 | |
| Boston Scientific Corporation | $37.16 | 2024 | Watchman Access System |
| Edwards Lifesciences Corporation | $34.46 | 2023-2025 | Sapien 3 Ultra Resilia |
| Abbvie INC. | $34.37 | 2022-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $30.48 | 2019 | |
| Amarin Pharma, INC. | $28.02 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $27.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.67 | 2019 | |
| Avanir Pharmaceuticals, INC. | $23.16 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.07 | 2019 | |
| Bioventus LLC | $14.03 | 2019 | |
| Acadia Pharmaceuticals INC | $13.44 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Honan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.